argatroban Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Argatroban is a synthetic direct thrombin inhibitor derived from L-arginine. Argatroban is a direct thrombin inhibitor that reversibly binds to the thrombin active site. Argatroban does not require the co-factor antithrombin III for antithrombotic activity. Argatroban exerts its anticoagulant effects by inhibiting thrombin-catalyzed or -induced reactions, including fibrin formation; activation of coagulation factors V, VIII, and XIII; protein C; and platelet aggregation. Argatroban is highly selective for thrombin with an inhibitory constant (Ki) of 0.04 µM. At therapeutic concentrations, Argatroban has little or no effect on related serine proteases (trypsin, factor Xa, plasmin, and kallikrein). Argatroban is capable of inhibiting the action of both free and clot-associated thrombin. Argatroban is indicated as an anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia. Argatroban is indicated as an anticoagulant in patients with or at risk for heparin-induced thrombocytopenia undergoing percutaneous coronary intervention (PCI).   NCATS

Chemistry

  • SMILES: C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)C2=CC=CC3=C2NCC(C)C3
  • InChIKey: KXNPVXPOPUZYGB-IOVMHBDKSA-N
  • Mol. Mass: 508.634
  • ALogP: 0.91
  • ChEMBL Molecule:
    argatroban  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$58.3933 - $430.7933
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

2-piperidinecarboxylic acid, 1-(5-((aminoiminomethyl)amino)-1-oxo-2-(((1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl)amino)pentyl)-4-methyl- | 4-methyl-1-(n(2)-(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-l-arginyl)-2-piperidinecarboxylic acid | acova | argatroban | argatroban hydrate | argatroban in sodium chloride | argatroban monohydrate | argatroban sodium | dk-7419 | gn1600 | gn-1600 | mci 9038 | mci-9038 | md805 | md 805 | md-805 | mmtqap | mpqa | novastan

Organizations (47)

Research & Development (27)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (21)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (19)

Approved Indications (2)


 

Thrombocytopenia

Thrombosis (approved 2000)

Experimental Indications - Clinical Trial Phases 1-4 (19)


 

Angina, Unstable (Phase 2)

Anticoagulants (Phase 2/Phase 3)

Blood Platelets (Phase 4)

Brain Ischemia (Phase 2)

Coronary Artery Disease (Phase 2)

COVID-19 (Phase 4)

Drugs, Investigational (Phase 4)

Extracorporeal Membrane Oxygenation (Phase 2/Phase 3)

General Surgery (Phase 4)

Genital Neoplasms, Female (Phase 3)

Heart Diseases (Phase 4)

Heparin, Low-Molecular-Weight (Phase 3)

Ischemic Stroke (Phase 4)

Kidney Failure, Chronic (Phase 4)

Staphylococcal Infections (Phase 2)

Stroke (Phase 4)

Thrombocytopenia ()

Thrombosis (Phase 4)

Venous Thromboembolism (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 27
  • # of Trial Organizations: 27

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue